Stockscreener 앱 받기
214.35
1.11%
-2.40
전일 마감가:
$216.75
열려 있는:
$215.61
하루 거래량:
8.59M
Relative Volume:
1.49
시가총액:
$378.84B
수익:
$59.64B
순이익/손실:
$2.36B
주가수익비율:
161.74
EPS:
1.3253
순현금흐름:
$19.68B
1주 성능:
-2.60%
1개월 성능:
-4.17%
6개월 성능:
+12.47%
1년 성능:
+23.40%
1일 변동 폭
$213.88
$217.34
1주일 범위
$213.88
$223.34
52주 변동 폭
$164.39
$244.81
애브비 Stock (ABBV) Company Profile
명칭
Abbvie Inc
전화
(847) 932-7900
주소
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
ABBV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
214.35 | 383.08B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
LLY
Lilly Eli Co
|
1,038.40 | 924.53B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
218.66 | 529.01B | 92.15B | 25.12B | 20.46B | 10.36 |
|
NVO
Novo Nordisk Adr
|
62.33 | 253.81B | 46.69B | 15.29B | 9.25B | 3.4329 |
|
NVS
Novartis Ag Adr
|
144.34 | 274.68B | 54.45B | 14.42B | 17.15B | 7.333 |
애브비 Stock (ABBV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-08 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-10 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-11-04 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2025-10-14 | 다운그레이드 | Erste Group | Buy → Hold |
| 2025-10-01 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-09-17 | 업그레이드 | Berenberg | Hold → Buy |
| 2025-08-12 | 재개 | Piper Sandler | Overweight |
| 2025-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-04 | 업그레이드 | Argus | Hold → Buy |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-06-05 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-05-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-01-29 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-12-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-30 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-07-25 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-05 | 다운그레이드 | Argus | Buy → Hold |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-22 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-11-08 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Underperform |
| 2022-05-06 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-02-28 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-03 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-03 | 재확인 | Barclays | Equal Weight |
| 2022-02-03 | 재확인 | BofA Securities | Neutral |
| 2022-02-03 | 재확인 | Goldman | Neutral |
| 2022-01-13 | 개시 | Redburn | Buy |
| 2022-01-12 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-11-23 | 업그레이드 | Societe Generale | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-23 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | 업그레이드 | Argus | Hold → Buy |
| 2020-05-18 | 재개 | BofA/Merrill | Neutral |
| 2020-05-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-05-11 | 재개 | Morgan Stanley | Overweight |
| 2020-04-20 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | 재확인 | Cowen | Outperform |
| 2019-09-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-20 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-04-29 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
모두보기
애브비 주식(ABBV)의 최신 뉴스
Could Buying This Stock Today Pay Off Big Over the Next 5 Years? - Finviz
Could Buying This Stock Today Pay Off Big Over the Next 5 Years? - The Motley Fool
Key facts: AbbVie to invest $100B in U.S. research; Phase 3 trial shows progress - TradingView — Track All Markets
AbbVie stock heads into long weekend lower after mixed Epkinly trial readout; earnings next - TechStock²
PRESCRIPTION DRUGS—N.D. Ill.: Complaint that AbbVie violated state consumer protection statutes dismissed - VitalLaw.com
AbbVie Call Options Spike 2,599%: Tracking the Big Bet - Finviz
AbbVie and Genmab Advance Epcoritamab with Significant PFS Improvement in DLBCL Trial - Intellectia AI
AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst - TechStock²
AbbVie Announces Topline Results for Epcoritamab from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma - Investing News Network
AbbVie (ABBV) Phase 3 Trial Shows Progression-Free Survival Impr - GuruFocus
Genmab and AbbVie's blood cancer drug fails to improve survival in late-stage study - TradingView — Track All Markets
Genmab down after trial data for AbbVie-partnered Epkinly in B-cell lymphoma - Seeking Alpha
AbbVie (ABBV) and Genmab Advance Epcoritamab Trials for Lymphoma - GuruFocus
AbbVie reports mixed results in phase 3 lymphoma trial By Investing.com - Investing.com Canada
AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) - Yahoo Finance
AbbVie Expands Oncology Pipeline With First-in-Human ABBV-711 Trial in Advanced Squamous Tumors - TipRanks
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Glaukos (GKOS) - The Globe and Mail
Zacks Research Comments on AbbVie's Q1 Earnings (NYSE:ABBV) - MarketBeat
JPM26: AbbVie highlights growth drivers as it moves away from Humira dependency - Pharmaceutical Technology
Rx Rundown: Nvidia, Johnson & Johnson, AbbVie and more - Medical Marketing and Media
AbbVie Inc.'s (NYSE:ABBV) institutional investors lost 3.3% last week but have benefitted from longer-term gains - Yahoo Finance
Investors Purchase Large Volume of AbbVie Call Options (NYSE:ABBV) - MarketBeat
AbbVie (ABBV) Stock Dips While Market Gains: Key Facts - Yahoo Finance
AbbVie (NYSE:ABBV) Shares Down 2.4%Time to Sell? - MarketBeat
Atopic Dermatitis Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regeneron Pharma, Abbvie, Allergan - Barchart.com
AbbVie stock slides 2% as obesity push takes center stage at JPM conference - TechStock²
10 Health Care Stocks Whale Activity In Today's Session - Benzinga
J.P. Morgan: AbbVie Still Aims To Be A Major Obesity Player – With A Lift From Botox - Citeline News & Insights
AbbVie Advances Obesity Pipeline With Completion of First-in-Human GUB014295 Trial - TipRanks
The Zacks Analyst Blog Highlights AbbVie, Intel, Boeing and Tandy Leather Factory - Yahoo Finance
BMO Capital reiterates Outperform rating on AbbVie stock amid growth By Investing.com - Investing.com UK
AbbVie Inc. $ABBV Shares Bought by Meritage Portfolio Management - MarketBeat
Why AbbVie Has Committed $100bn to US Medicine Supply Chains - Procurement Magazine
How AbbVie’s $100bn Investment Reshapes Pharma Supply Chains - Supply Chain Digital Magazine
AbbVie’s US$100bn Deal Could Transform US Healthcare Access - Healthcare Digital
Conning Inc. Decreases Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Seeks To Grow Obesity Drug Portfolio — Retail Touts Drugmaker As Big Competition To Lilly - Stocktwits
AbbVie: stepping up obesity treatments with an alternative approach to GLP-1 - marketscreener.com
Rep. Julia Letlow Sells Off Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie stock in focus after hours as it eyes obesity market — what to watch next - TechStock²
Top Research Reports for AbbVie, Intel & Boeing - Yahoo Finance
AbbVie plans to build out its presence in obesity market - Reuters
AbbVie Reaches Agreement With Trump Administration, Joining MFN Initiatives - Pharmacy Times
AbbVie to invest $100 billion in the U.S in exchange for tariff exemptions - The American Bazaar
JP Morgan 2026: AbbVie Advances its Pipeline - PharmExec.com
Key facts: AbbVie Reports Growth in Immunology, Neuroscience; Targets Weight-Loss Market - TradingView — Track All Markets
AbbVie sets sights on immunology, neurology dominance - Crain's Chicago Business
AbbVie Bets Big on Chinese Cancer Drug in $5.6 Billion Licensing Deal - Caixin Global
AbbVie Joins TrumpRx in Exchange for Tariff Relief and Pricing Flexibility - Pharmaceutical Commerce
AbbVie (ABBV) Rises on Agreement for Drug Pricing and Investment Commitment - GuruFocus
Ex-Dividend Reminder: AbbVie, Dime Community Bancshares and MidWestOne Financial Group - Nasdaq
애브비 (ABBV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
9.12%
1.93%
자본화:
|
볼륨(24시간):